Cargando…
Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events
PURPOSE: To assess safety and effectiveness of anti-tumor necrosis factor (anti-TNF) therapy in IBD patients ≥ 60 years. METHODS: Ninety IBD patients ≥ 60 years at initiation of anti-TNF therapy, 145 IBD patients ≥ 60 years without anti-TNF therapy and 257 IBD patients < 60 years at initiation of...
Autores principales: | Asscher, Vera E. R., van der Vliet, Quirine, van der Aalst, Karen, van der Aalst, Anniek, Brand, Eelco C., van der Meulen-de Jong, Andrea E., Oldenburg, Bas, Pierik, Marieke J., van Tuyl, Bas, Mahmmod, Nofel, Maljaars, P. W. Jeroen, Fidder, Herma H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648742/ https://www.ncbi.nlm.nih.gov/pubmed/32860081 http://dx.doi.org/10.1007/s00384-020-03716-6 |
Ejemplares similares
-
Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease
por: Schultheiss, Johannes P. D., et al.
Publicado: (2021) -
Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up
por: van der Valk, Mirthe E., et al.
Publicado: (2016) -
Process Mining : Discovery, Conformance and Enhancement of Business Processes
por: Aalst, Wil van der
Publicado: (2011) -
Process mining : data science in action
por: Aalst, Wil van der
Publicado: (2016) -
Process mining: data science in action
por: van der Aalst, Wil
Publicado: (2016)